J Rhet Tucker1, Li Xu2, Erich M Sturgis2, Abdallah S R Mohamed3, Theresa M Hofstede1, Mark S Chambers1, Stephen Y Lai2, Clifton David Fuller4, Beth Beadle4, G Brandon Gunn4, Katherine A Hutcheson5. 1. Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Section of Oral Oncology and Maxillofacial Prosthodontics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 2. Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 3. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Clinical Oncology and Nuclear Medicine, Alexandria University, Alexandria, Egypt. 4. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 5. Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Section of Speech Pathology and Audiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: karnold@mdanderson.org.
Abstract
PURPOSE: The present study was undertaken to evaluate osteoradionecrosis (ORN) in patients with salivary gland malignancies (SGM) after treatment with radiation therapy. MATERIALS AND METHODS: The medical records of 172 patients treated with radiation therapy for SGM during a 12-year period (August 2001 to November 2013) were reviewed. Incidence, time to event, staging and management of ORN were analyzed. RESULTS: Of the 172 patients, 7 patients (4%) developed ORN (median latency: 19months, range: 4-72months). Of those 7 patients, 4 required major surgery, 1 required hyperbaric oxygen therapy (HBO), one required minor debridement, and one required conservative management. Total prescribed radiation dose varied from 50Gy (1 case) to 70Gy (1 case) among those patients who developed ORN, and radiotherapy was delivered postoperatively after osseous resection in 4 of 7 cases. Three of the 7 cases of ORN occurred after traumatic injury to the bone. Of the 7 patients who developed ORN, 3 had SGM of the major glands, 3 had other sites of the oral cavity, and 1 had a sinonasal location. CONCLUSION: While the rate of ORN after radiotherapy for SGM was somewhat lower (4%) than previously published data on patients with squamous cell carcinomas of the head and neck treated with radiation therapy (8-14%), ORN necessitating major surgery remains a clinically significant, possible late effect of radiotherapy in SGM survivors. Location of SGM is very important, with cases that developed ORN disproportionally having primary disease arising in the oral cavity.
PURPOSE: The present study was undertaken to evaluate osteoradionecrosis (ORN) in patients with salivary gland malignancies (SGM) after treatment with radiation therapy. MATERIALS AND METHODS: The medical records of 172 patients treated with radiation therapy for SGM during a 12-year period (August 2001 to November 2013) were reviewed. Incidence, time to event, staging and management of ORN were analyzed. RESULTS: Of the 172 patients, 7 patients (4%) developed ORN (median latency: 19months, range: 4-72months). Of those 7 patients, 4 required major surgery, 1 required hyperbaric oxygen therapy (HBO), one required minor debridement, and one required conservative management. Total prescribed radiation dose varied from 50Gy (1 case) to 70Gy (1 case) among those patients who developed ORN, and radiotherapy was delivered postoperatively after osseous resection in 4 of 7 cases. Three of the 7 cases of ORN occurred after traumatic injury to the bone. Of the 7 patients who developed ORN, 3 had SGM of the major glands, 3 had other sites of the oral cavity, and 1 had a sinonasal location. CONCLUSION: While the rate of ORN after radiotherapy for SGM was somewhat lower (4%) than previously published data on patients with squamous cell carcinomas of the head and neck treated with radiation therapy (8-14%), ORN necessitating major surgery remains a clinically significant, possible late effect of radiotherapy in SGM survivors. Location of SGM is very important, with cases that developed ORN disproportionally having primary disease arising in the oral cavity.
Authors: Daniel R Gomez; Cherry L Estilo; Suzanne L Wolden; Michael J Zelefsky; Dennis H Kraus; Richard J Wong; Ashok R Shaha; Jatin P Shah; James G Mechalakos; Nancy Y Lee Journal: Int J Radiat Oncol Biol Phys Date: 2011-05-11 Impact factor: 7.038
Authors: Merav A Ben-David; Maximiliano Diamante; Jeffrey D Radawski; Karen A Vineberg; Cynthia Stroup; Carol-Anne Murdoch-Kinch; Samuel R Zwetchkenbaum; Avraham Eisbruch Journal: Int J Radiat Oncol Biol Phys Date: 2007-02-22 Impact factor: 7.038
Authors: Youssef H Zeidan; Leonid Pekelis; Yi An; Floyd Christopher Holsinger; Christina S Kong; Daniel T Chang; Quynh-Thu Le Journal: Oral Oncol Date: 2015-03-11 Impact factor: 5.337
Authors: Beth M Beadle; Kai-Ping Liao; Mark S Chambers; Linda S Elting; Thomas A Buchholz; K Kian Ang; Adam S Garden; B Ashleigh Guadagnolo Journal: Head Neck Date: 2012-11-14 Impact factor: 3.147
Authors: Ik Jae Lee; Woong Sub Koom; Chang Geol Lee; Yong Bae Kim; Sei Whan Yoo; Ki Chang Keum; Gwi Eon Kim; Eun Chang Choi; In Ho Cha Journal: Int J Radiat Oncol Biol Phys Date: 2009-03-26 Impact factor: 7.038
Authors: Victor M Duarte; Yuan F Liu; Sassan Rafizadeh; Tracey Tajima; Vishad Nabili; Marilene B Wang Journal: Otolaryngol Head Neck Surg Date: 2013-10-21 Impact factor: 3.497
Authors: Chiaojung Jillian Tsai; Theresa M Hofstede; Erich M Sturgis; Adam S Garden; Mary E Lindberg; Qingyi Wei; Susan L Tucker; Lei Dong Journal: Int J Radiat Oncol Biol Phys Date: 2012-07-12 Impact factor: 7.038
Authors: Souptik Barua; Hesham Elhalawani; Stefania Volpe; Karine A Al Feghali; Pei Yang; Sweet Ping Ng; Baher Elgohari; Robin C Granberry; Dennis S Mackin; G Brandon Gunn; Katherine A Hutcheson; Mark S Chambers; Laurence E Court; Abdallah S R Mohamed; Clifton D Fuller; Stephen Y Lai; Arvind Rao Journal: Front Artif Intell Date: 2021-04-09